FAIR LAWN, NJ–(Marketwire – August 10, 2010) – Vyteris, Inc. ( OTCBB : VYTR ), developer of the first FDA-approved active transdermal patch and a leader in alternative drug delivery technology, today announced positive results from a Phase II clinical trial evaluating the safety and efficacy of a pulsatile delivery system for the treatment of female infertility, based on the Company’s smart …
Categories
- Andropause
- Anti-Aging Medicine
- Biotechnology
- Endocrinology
- Exercise And Fitness
- Gene therapy
- HCG Therapy
- Hormone Replacement Therapy
- Infertility
- Integrative Medicine
- Longevity
- Longevity Medicine
- Menopause Management
- Nutraceuticals
- Nutrition
- Preventative Medicine
- Regenerative Medicine
- Sexual Dysfunction
- Stem Cell Therapy
- Testosterone
- Weight Management
Archives